gdc
Immunotherapy

Immunotherapy vs Targeted Therapy

Dr Morganna Freeman explains the difference between immunotherapies and targeted therapies in plain language for patients to easily understand.
Video Library – January 10, 2019
Morganna Freeman, DO, FACP

Dr Morganna Freeman explains the difference between immunotherapies and targeted therapies in plain language for patients to easily understand.

Recommended For You
Immunotherapy
Why Target the Immune System?
By Colleen H. Erb, MSN, CRNP, ACNP-BC, AOCNP
The immune system attacks foreign substances by making large numbers of antibodies. These are proteins that attach to a specific protein on the cell called an antigen.
ImmunotherapyMultiple Myeloma
How CAR T-Cell Therapy Gave Cherie Rineker Her Life Back
By Kelsey Moroz
Chemotherapy for multiple myeloma had kept Cherie Rineker alive for 5 years, but then she realized she was slowly dying. So she embarked on a search for a clinical trial and by luck was able to join one. To her amazement, “What 2 stem-cell transplants and 13 other treatments had not been able to do in more than 65 months, CAR T-cell therapy did in less than 1 month,” she said.
Breast CancerFDA Approvals, News & UpdatesImmunotherapy
First Immunotherapy Approved for Patients with Advanced or Metastatic Triple-Negative Breast Cancer Expressing PD-L1
In March 2019, the FDA approved Tecentriq (atezolizumab), a PD-L1 inhibitor, in combination with Abraxane (paclitaxel protein-bound), for use in adults with locally advanced or metastatic triple-negative breast cancer whose tumors cannot be removed by surgery and express PD-L1, as identified by an FDA-approved test. This is the first FDA-approved immunotherapy for patients with advanced or metastatic triple-negative breast cancer.
Last modified: February 27, 2019

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country